Brainreader and Phenome Health announce exclusive partnership – Negotiations Continue as Million Person Trial design advances

Press Release, Copenhagen, Denmark – November 29, 2022

Brainreader today announced that it is in advanced negotiations to utilize Neuroreader® as the sole source of volumetric brain analytics for Phenome Health, founded by Lee Hood, PhD.

The proposed collaboration would support Phenome Health’s Beyond the Human Genome Project, a landmark one-million-person, ten-year trial designed to redefine the understanding, prevention, and treatment of dementia and brain health worldwide.

About the Million-Person Brain Health Trial

Phenome Health is planning a large-scale, dementia-focused clinical research initiative expected to examine approximately 100,000 participants annually. The trial is designed to generate unprecedented longitudinal brain health data, integrating imaging, molecular biology, and clinical insights.

The scientific and cultural significance of the project is reinforced by the upcoming book by Lee Hood and Nathan Price, The Age of Scientific Wellness, published by Harvard University Press (April 4, 2023).

Expert Commentary

Dr. Hood, co-founder of the Institute for Systems Biology and recipient of the National Medal of Science, commented:

“Neuroreader® has proven to be more detailed and efficient than alternative brain volumetric software reviewed, and we are happy to undertake the design of an agreement with Brainreader for this game-changing trial.”

Mads Fiig, CEO of Brainreader, added:

“We are very excited about the opportunity to work on this revolutionary trial with Dr. Hood and his forward-looking scientific team.”

Why This Partnership Matters

If finalized, this collaboration would:

• Support large-scale, longitudinal brain volumetric analysis
• Advance data-driven dementia research and prevention
• Enable consistent, automated MRI volumetrics across global cohorts
• Accelerate translation of brain imaging data into clinical insights

The trial is expected to influence future standards in dementia research, systems biology, and preventive neuroscience.

About Brainreader

Brainreader is the U.S. subsidiary of its Danish parent company. Its flagship product, Neuroreader®, is a patented, FDA-cleared, and CE-marked medical software that post-processes MRI scans to detect abnormal brain patterns through automated volumetric analysis.

The Neuroreader® Report delivers customizable, quantitative brain volume measurements designed to support the detection of neurodegenerative disease and guide clinical decision-making.

​